NAFLD and Hepatic Inflammation: Multi-modal MR-Investigations of Disease Progression
Christian Simonsson1,2,3, Markus Karlsson2,3, Patrik Nasr3,4, Ralph Sinkus 5,6, Simone Ignatova7, Nils Dahlström2,3, Mattias Ekstedt3,4, Stergios Kechagias3,4, and Peter Lundberg2,3
1Department of Biomedical Engineering (IMT), Linköping University, Linköping, Sweden, 2Department of Radiation Physics, Radiology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, 3Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden, 4Department of Gastroenterology and Hepatology, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden, 5Imaging Sciences & Biomedical Engineering, Kings College, London, United Kingdom, 6LVTS, INSERM U1148, Paris, France, 7Department of Clinical Pathology and Clinical Genetics, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
Several MR-biomarkers characterizing different aspects of NAFLD progression, especially for the early onset, and late stages, are available. However, there is a need to combine and characterize, not only the endpoints but also the intermediate stages of the disease, in particular the early stages of hepatic inflammation. Using an extensive multi-modal MRI protocol, we have investigated correlations between different MR-biomarkers with histopathology measurements of hepatic inflammation, fat accumulation and fibrosis. The long-term aim of this research is to characterize each patient in the early to intermediate stages of disease progression, with a higher degree of precision.
This abstract and the presentation materials are available to members only;
a login is required.